Luo Yinggang, Lin Shuangjun, Zhang Jian, Cooke Heather A, Bruner Steven D, Shen Ben
Division of Pharmaceutical Sciences, University of Wisconsin National Cooperative Drug Discovery Group, Department of Chemistry, University of Wisconsin, Madison, WI 53705, USA.
J Biol Chem. 2008 May 23;283(21):14694-702. doi: 10.1074/jbc.M802206200. Epub 2008 Apr 3.
Neocarzinostatin, a clinical anticancer drug, is the archetypal member of the chromoprotein family of enediyne antitumor antibiotics that are composed of a nonprotein chromophore and an apoprotein. The neocarzinostatin chromophore consists of a nine-membered enediyne core, a deoxyaminosugar, and a naphthoic acid moiety. We have previously cloned and sequenced the neocarzinostatin biosynthetic gene cluster and proposed that the biosynthesis of the naphthoic acid moiety and its incorporation into the neocarzinostatin chromophore are catalyzed by five enzymes NcsB, NcsB1, NcsB2, NcsB3, and NcsB4. Here we report the biochemical characterization of NcsB1, unveiling that: (i) NcsB1 is an S-adenosyl-L-methionine-dependent O-methyltransferase; (ii) NcsB1 catalyzes regiospecific methylation at the 7-hydroxy group of its native substrate, 2,7-dihydroxy-5-methyl-1-naphthoic acid; (iii) NcsB1 also recognizes other dihydroxynaphthoic acids as substrates and catalyzes regiospecific O-methylation; and (iv) the carboxylate and its ortho-hydroxy groups of the substrate appear to be crucial for NcsB1 substrate recognition and binding, and O-methylation takes place only at the free hydroxy group of these dihydroxynaphthoic acids. These findings establish that NcsB1 catalyzes the third step in the biosynthesis of the naphthoic acid moiety of the neocarzinostatin chromophore and further support the early proposal for the biosynthesis of the naphthoic acid and its incorporation into the neocarzinostatin chromophore with free naphthoic acids serving as intermediates. NcsB1 represents another opportunity that can now be exploited to produce novel neocarzinostatin analogs by engineering neocarzinostatin biosynthesis or applying directed biosynthesis strategies.
新制癌菌素是一种临床抗癌药物,是烯二炔类抗肿瘤抗生素中色蛋白家族的典型成员,这类抗生素由一个非蛋白发色团和一个脱辅基蛋白组成。新制癌菌素发色团由一个九元烯二炔核心、一个脱氧氨基糖和一个萘甲酸部分组成。我们之前已经克隆并测序了新制癌菌素生物合成基因簇,并提出萘甲酸部分的生物合成及其掺入新制癌菌素发色团是由五种酶NcsB、NcsB1、NcsB2、NcsB3和NcsB4催化的。在此,我们报告了NcsB1的生化特性,揭示了:(i)NcsB1是一种依赖S-腺苷-L-甲硫氨酸的O-甲基转移酶;(ii)NcsB1催化其天然底物2,7-二羟基-5-甲基-1-萘甲酸的7-羟基进行区域特异性甲基化;(iii)NcsB1也将其他二羟基萘甲酸识别为底物并催化区域特异性O-甲基化;(iv)底物的羧酸盐及其邻位羟基对于NcsB1底物识别和结合似乎至关重要,并且O-甲基化仅发生在这些二羟基萘甲酸的游离羟基上。这些发现确定NcsB1催化新制癌菌素发色团萘甲酸部分生物合成的第三步,并进一步支持了早期关于萘甲酸生物合成及其以游离萘甲酸为中间体掺入新制癌菌素发色团的提议。NcsB1代表了另一个机会,现在可以通过改造新制癌菌素生物合成或应用定向生物合成策略来利用这个机会生产新型新制癌菌素类似物。